Clinical Reasoning: A Young Man With Subacute Onset of Spastic Paraparesis

Salvatore Rossi, MD, Paola Concolino, PhD, Daniele Di Natale, MD, Domizia Pasquetti, MD, Giuseppe Maria Di Lella, MD, PhD, Pietro Chiurazzi, MD, PhD, and Gabriella Silvestri, MD, PhD

Neurology® 2023;100:199-205. doi:10.1212/WNL.0000000000201516

Abstract

Leukodystrophies are a group of rare neurodegenerative disorders, usually presenting in infancy with a variable combination of cognitive, motor, and coordination impairment. Adult-onset cases are even more rare, often representing a diagnostic challenge even for experienced neurologists. Here, we present a case of a 44-year-old man with subacute and rapidly progressive spastic paraplegia, whose brain MRI revealed white matter abnormalities compatible with a diagnosis of leukodystrophy. We discuss how to apply a simplified diagnostic algorithm to distinguish acquired leukoencephalopathies from leukodystrophies and how to delve into the maze of genetic testing for white matter diseases. In our patient, we reached the diagnosis of a treatable disorder, whose early recognition is essential to prevent severe neurologic deterioration.
Section 1

A 44-year-old man born to nonconsanguineous parents presented with subacute onset and rapidly progressive walking difficulties requiring the need for 1 walking cane 4 months after onset, along with urinary incontinence and erectile dysfunction. He was affected by autosomal dominant polycystic kidney disease associated with a pathogenic variant in PKD1 inherited from his mother. His father died at the age of 62 years of colorectal cancer. The proband required educational support at school but was able to achieve a secondary school degree. He had stable employment and participated in regular weight-lifting exercise.

The first neurologic evaluation at our center 18 months from the onset of symptoms showed spastic paraparesis requiring canes to walk. Lower limb weakness was moderate (bilaterally grade 4 by the Medical Research Council scale at iliopsoas and tibialis anterior muscles), and spasticity was marked (modified Ashworth scale = 3 bilaterally). The Spastic Paraplegia Rating Scale score was 26. No muscle atrophy or fasciculations were evident. Deep tendon limb reflexes were brisk (3+) in all extremities, and Hoffman and Babinski signs were present bilaterally. Upper limb, cranial nerve, and sensory function were all normal.

Question for Consideration:
1. Which is the most appropriate first-line investigation in this case?
Section 2

First, as spastic paraplegia was accompanied by brisk reflexes also in upper limbs, spinal cord MRI was performed to address possible cervical myelopathy or other structural lesions at that level, resulting normal (Figure). Next, brain MRI was performed, showing extensive T2 hyperintensity involving deep, mainly posterior, white matter (WM), with corresponding slightly hypointense T1 signal and sparing of the subcortical U-fibers and corpus callosum (Figure). Mild cerebellar atrophy was also present. MR spectroscopy (MRS) did not show any abnormal peaks. Gadolinium contrast was not infused because of chronic kidney disease.

Electroneurography documented axonal sensory and demyelinating motor polyneuropathy. EEG showed generalized background theta slowing. Ophthalmologic examination was normal.

**Question for Consideration:**
1. Is the brain MRI in this clinical picture suggestive of an acquired WM disorder or a genetic leukoencephalopathy?

---

**Figure** Brain and Spine MRI of the Proband

Panel showing T2-weighted (A, C) and T1-weighted (B, D) axial brain MRI scans at the basal ganglia (A, B) and centrum semiovale (C, D) level. An extensive and symmetric T2 hyperintensity (A, C) involving mainly occipital and parietal white matter, with corresponding T1 slightly hypointense signal (B) and sparing of the subcortical U-fibers and corpus callosum, is depicted. (E) T2-weighted sagittal brain MRI scans showing mild vermian cerebellar atrophy. (F) T2-weighted sagittal MRI scans of the spinal cord.
Section 3

In our patient, the subacute and aggressive course of spastic paraplegia warranted exclusion of acquired causes of WM disease, namely of inflammatory, toxic/metabolic, and neoplastic etiologies. Neurologic manifestations did not appear to be related to the concomitant PKD1 disease, as even if kidney function was reduced, blood pressure was under good control.

Symmetry, confluence, and sparing of some structures (U-fibers, corpus callosum, spinal cord, and juxtacortical WM) were inconsistent with a diagnosis of multiple sclerosis. JC virus–related progressive multifocal leukoencephalopathy was also unlikely, given that our patient has never been immunosuppressed.

Both drug abuse (heroin and methanol) and exposure to radiotherapy/chemotherapy (5-fluorouracil and methotrexate) may cause confluent, symmetrical WM abnormalities; however, such etiologies were implausible in our patient.

Primary CNS lymphoma and gliomatosis cerebri may cause extensive WM brain abnormalities. In the former condition, brain MRI shows hypointense T1 signal, isointense to hypointense T2 signal, and vivid contrast enhancement, often exhibiting crossing of the corpus callosum. In gliomatosis cerebri, a rare tumor involving at least 3 lobes, minimal mass effect and enhancement are found. The long medical history of our patient made both hypotheses unlikely, even in the absence of contrast-enhanced images.

The initial diagnostic workup of any subacute onset and progressive WM disorder should include serology for HIV, syphilis, hepatitis B/C, tuberculosis, JC virus, looking for autoimmune antibodies, blood lactate, folate and vitamin B12, and CSF examination looking for oligoclonal bands. All these test results were negative.

Also, one should consider cerebral small vessel disease that can be acquired or inherited. The acquired form usually relates to exposure to long-standing cardiovascular risk factors; conversely, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL/NOTCH3), autosomal recessive cerebral arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL/HTRA1), collagen type IV/COL4A variants, and Fabry disease/GLA represent etiologies of inherited forms. In cerebral small vessel disease, brain MRI initially shows multifocal, bilateral patchy WM abnormalities, merging to confluent WM lesions later in the disease course. However, basal ganglia, thalami, and brainstem are invariably affected, and microbleeds are commonly observed on gradient echo and susceptibility-weighted scans. All these features were absent in our case.

Thus, confluent, bilateral, symmetric supratentorial WM abnormalities suggested a genetic WM disorder, namely a leukodystrophy.

Question for Consideration:
1. How do you approach genetic testing for leukodystrophies?
Section 4

Adult-onset leukodystrophies may have nonspecific presentations, including variable combinations of cognitive decline, spasticity, and ataxia.6,7 Most leukodystrophies are slowly progressive, yet some forms may present abruptly, as cerebral adrenoleukodystrophy/ABCD1 and vanishing white matter/EIF2B. Cerebral adrenoleukodystrophy was promptly excluded by normal levels of plasma very long chain fatty acids, adrenocorticotropic hormone, and cortisol, whereas vanishing white matter disease was considered unlikely, as in our patient neurologic deterioration was not preceded by infections or head trauma, and brain MRI did not show cavitating leukoencephalopathy.1,6

Notwithstanding the advantage given by next-generation sequencing (NGS) techniques, some discriminating clues are still fundamental in the diagnostic workup of adult-onset leukodystrophies (Table) because some forms are associated with major genomic structural rearrangements not detectable by standard NGS. This is the case of an autosomal dominant adult-onset leukodystrophy characterized by early dysautonomia combined with spasticity and related to duplication of LMNB1, detectable only by multiplex ligation-dependent probe amplification. We specifically searched for it in our patient, with negative results.1

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia type 1 or 2, caused by autosomal dominant variants in CSF1R or AARS2, respectively, may be also rapidly progressive: both forms are characterized by extremely small, symmetric calcifications, better detected by brain CT, mainly located in the frontoparietal subcortical WM, with basal ganglia sparing.8 Again, in our patient, a normal brain CT made this condition unlikely.

CNS hypomyelination is suggested if the T2/FLAIR WM hyperintensity is diffuse, and the corresponding signal in T1 images is isointense, mildly hypointense, or hyperintense, in contrast to demyelinating disorders in which the WM displays invariably hypointense T1 signal.9 The most common form of hypomyelinating leukodystrophy, Pelizaeus-Merzbacher disease due to duplication of PLP1, was not investigated because it is an extremely severe, usually very early-onset form of X-linked

### Table Differential Diagnosis of Main Adult-Onset Leukodystrophies

<table>
<thead>
<tr>
<th>Disease (gene)</th>
<th>Distinguishing features (brain MRI pattern)</th>
<th>Look for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenoleukodystrophy (ABCD1)</td>
<td>Possible rapid deterioration, possible Addisonian crisis, and polyneuropathy (parieto-occipital, contrast enhancement)</td>
<td>Serum very long chain fatty acids (1)</td>
</tr>
<tr>
<td>Vanishing white matter (EIF2B)</td>
<td>Possible optic nerve atrophy (diffuse brain involvement, cavitating leukoencephalopathy, and corpus callosum thinning)</td>
<td></td>
</tr>
<tr>
<td>Autosomal dominant adult-onset demyelinating leukodystrophy (duplication of LMNB1)</td>
<td>Autonomic dysfunction (frontal predominance)</td>
<td>Single-gene testing by MLPA (not detected by NGS)</td>
</tr>
<tr>
<td>Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia type 1 and 2 (CSF1R or AARS2)</td>
<td>Early-onset dementia and polyneuropathy (bifrontal/bifrontoparietal involvement, calcifications, asymmetric lesions, and corpus callosum thinning)</td>
<td></td>
</tr>
<tr>
<td>Pelizaeus-Merzbacher disease (duplication of PLP1)</td>
<td>Torsional nystagmus and polyneuropathy (hypomyelination and atigroid pattern)</td>
<td>Single-gene testing by MLPA (not detected by NGS)</td>
</tr>
<tr>
<td>Leukoencephalopathy with brainstem and spinal cord involvement with elevated lactate (DARS2)</td>
<td>Long-tract involvement and lactate peak at brain MRI spectroscopy</td>
<td></td>
</tr>
<tr>
<td>Alexander disease (GFAP)</td>
<td>Early bulbar symptoms (cerebellar involvement, frontal predominance, and possible contrast enhancement)</td>
<td>GFAP in CSF (1)</td>
</tr>
<tr>
<td>Cerebrotendinous xanthomatosis (CYP27A1)</td>
<td>Sclerotic ataxia, cataracts, chronic diarrhea, xanthomas, and polyneuropathy (denticulate nuclei hyperintensities)</td>
<td>Serum cholestanol (1)</td>
</tr>
<tr>
<td>Krabbe disease (GALC)</td>
<td>Possible optic nerve atrophy (periventricular and parieto-occipital predominance)</td>
<td>Leukocytes galactocerebrosidase activity (1)</td>
</tr>
<tr>
<td>Adult polyglucosan body disease (GBE1)</td>
<td>Upper and lower motor neuron impairment (periventricular and asymmetric predominance)</td>
<td>Leukocytes glycogen-branching enzyme activity (1)</td>
</tr>
<tr>
<td>Metachromatic leukodystrophy (ARSA/PSAP)</td>
<td>Early-onset dementia, possible rapid deterioration, possible optic nerve atrophy, polyneuropathy, and gallbladder dysfunction (periventricular and frontal predominance)</td>
<td>Leukocytes arylsulfatase A activity (1), urinary sulfates (1)</td>
</tr>
<tr>
<td>Gordon Holmes syndrome (POL3)</td>
<td>Hypodontia and delayed or absent puberty (hypomyelination)</td>
<td>Hypogonadotropic hypogonadism</td>
</tr>
<tr>
<td>Methyleneetrahydrofolate reductase deficiency (MTHFR)</td>
<td>Bilateral posterior prevalence</td>
<td>Serum homocysteine (1)</td>
</tr>
</tbody>
</table>

Copyright © 2023 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
leukodystrophy, with a characteristic tigroid pattern on the brain MRI and peculiar torsional nystagmus. Similarly, normal MRS made leuкоencephalopathy with brainstem and spinal cord involvement with elevated lactate (due to DARS2 variants) unlikely.

Besides plasma levels of very long chain fatty acids, other metabolic tests easily performed on peripheral blood or urine may help in the differential diagnosis of adult-onset leukodystrophies manifesting with spastic paraparesis associated with peripheral neuropathy, including galactocerebrosidase, glycogen-branching enzyme, and arylsulfatase activity in leucocytes (reduced in Krabbe disease, adult polycyclusan body disease, and metachromatic leukodystrophy, due to variants in GALC, GBE1, and ARSA/PSAP, respectively); serum cholestanol (raised in cerebrotendinous xanthomatosis, due to POLR3 variants); and gonadotropins and free testosterone (both reduced in Gordon Holmes syndrome, due to POLR3 variants); and homocysteine (raised in methylene tetrahydrofolate reductase deficiency, due to MTHFR variants). All these tests were normal in our case.

An initial diagnostic NGS approach by a targeted resequencing panel tailored for leukodystrophies gave negative results. Therefore, clinical exome was performed, leading to the identification of 2 pathogenic variants in PAH: c.842C>T p.(Pro281-Leu), inherited from his mother, and c.143T>C p.(Leu48Ser), presumably inherited from the deceased father. Molecular diagnosis of phenylketonuria (PKU) was made and confirmed by plasmatic hyperphenylalaninemia (1,592 μmol/L). After an unsuccessful 1-month trial of tetrahydrobiopterin (BH4), a low phenylalanine diet was started, with stabilization of the patient’s motor performances at the 3-month follow-up visit.

Discussion
PKU, also known as phenylalanine hydroxylase (PAH) deficiency (OMIM 261600), is a rare autosomal recessive inborn error of phenylalanine metabolism. PAH is responsible for the conversion of phenylalanine to tyrosine. Infants with PKU are normal at birth but, if untreated, invariably develop intellectual disability, epilepsy, aberrant behavior, and psychiatric symptoms. PKU mainly affects brain WM because related hyperphenylalaninemia alters the synthesis of brain lipids that form myelin. In Italy, a mandatory, nationwide, population-based newborn blood screening for PKU was introduced in 1992, 15 years after the birth of our patient.

Most patients with PKU are compound heterozygotes for different PAH pathogenic variants, mainly missense changes expected to impair PAH enzymatic activity. Genetic heterogeneity and compound heterozygosity lead to a wide phenotypic spectrum in PAH deficiency, in which patients with mild PKU can be responsive to BH4. Thus, PAH genotyping and genotype–phenotype studies may help to predict responsiveness to BH4, which can substitute low phenylalanine diet. In our case, both variants have been associated with both classic (55%) and mild (45%) PKU forms; nevertheless, the mild, late-onset clinical presentation and the predicted BH4 sensitivity of the c.143T>C variant supported the choice of BH4 as the first therapeutic option, whose lack of response shifted treatment toward low phenylalanine diet.

Regarding PKU, the availability of a specific treatment may improve symptoms and/or prevent further disease progression,12,13 so neurologists should be aware that undiagnosed adult-onset PKU can still occur in developed countries among individuals born before the establishment of PKU screening programs and among migrants from developing countries. In conclusion, plasma aminoacidogram should be part of the diagnostic panel of progressive leukoencephalopathies.

Acknowledgment
The authors thank Prof. Glen W. McWilliams and Dr. Stephanie Efthymiou for revising the English form of the manuscript.

Study Funding
The authors report no targeted funding.

Disclosure
The authors report no disclosures relevant to the manuscript.

Publication History
Received by Neurology April 5, 2022. Accepted in final form September 20, 2022. Submitted and externally peer reviewed. The handling editor was Whitley Aamodt, MD, MPH.

Appendix Authors
<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salvatore Rossi, MD</td>
<td>Dipartimento di Scienze dell’Invecchiamento, Neurologiche, Ortopediche della Testa-Collo, UOC Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Dipartimento di Neuroscienze Università Cattolica del Sacro Cuore, Facoltà di Medicina e Chirurgia, Rome, Italy</td>
<td>Drafting/revision of the manuscript for content; including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data.</td>
</tr>
<tr>
<td>Paola Concolino, PhD</td>
<td>UOC Chimica, Biochimica e Biologia Molecolare Clinica - Area Diagnostica di Laboratorio, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy</td>
<td>Analysis or interpretation of data.</td>
</tr>
<tr>
<td>Daniele Di Natale, MD</td>
<td>Dipartimento di Scienze dell’Invecchiamento, Neurologiche, Ortopediche della Testa-Collo, UOC Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Dipartimento di Neuroscienze Università Cattolica del Sacro Cuore, Facoltà di Medicina e Chirurgia, Rome, Italy</td>
<td>Drafting/revision of the manuscript for content; including medical writing for content.</td>
</tr>
</tbody>
</table>
Appendix (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domizia Pasquetti, MD</td>
<td>Istituto di Medicina Genomica, Università Cattolica del Sacro Cuore, Rome, Italy</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content</td>
</tr>
<tr>
<td>Giuseppe Maria Di Lella, MD, PhD</td>
<td>Department of Diagnostic Imaging, Oncological Radiotherapy, and Hematology, UOC Neuroradiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Università Cattolica del Sacro Cuore, 00168 Rome, Italy</td>
<td>Analysis or interpretation of data</td>
</tr>
<tr>
<td>Pietro Chiurazzi, MD, PhD</td>
<td>Istituto di Medicina Genomica, Università Cattolica del Sacro Cuore, Rome, Italy; UOC Genesica Medica, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content</td>
</tr>
<tr>
<td>Gabriella Silvestri, MD, PhD</td>
<td>Dipartimento di Scienze dell’Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, UOC Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Dipartimento di Neuroscienze Università Cattolica del Sacro Cuore, Facoltà di Medicina e Chirurgia, Rome, Italy</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data</td>
</tr>
</tbody>
</table>

References


Subspecialty Alerts by E-mail!

Customize your online journal experience by signing up for e-mail alerts related to your subspecialty or area of interest. Access this free service by clicking on the “My Alerts” link on the home page. An extensive list of subspecialties, methods, and study design choices will be available for you to choose from—allowing you priority alerts to cutting-edge research in your field!

Did You Know...

...you can browse by subspecialty topics on Neurology.org?

Go to: Neurology.org and click on “Collections” in the top navigation bar, then choose “Topics A-Z” from the drop down menu.